GPNMB and exanthem: In the case of glembatumumab vedotin that targets the transmembrane glycoprotein NMB (gpNMB) on cancer cells, development of skin rash was one of the observed dose-limiting toxicities, which is likely due to membrane expression of gpNMB in epithelial cells of the skin.